GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Cyclically Adjusted Price-to-FCF

Veru (STU:FMW) Cyclically Adjusted Price-to-FCF : (As of Jun. 09, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Veru Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Veru Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Veru's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Veru Cyclically Adjusted Price-to-FCF Chart

Veru Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.22 33.25 255.14 - -

Veru Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Veru's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Veru's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Veru's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Veru's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Veru's Cyclically Adjusted Price-to-FCF falls into.



Veru Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Veru's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Veru's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.036/131.7762*131.7762
=-0.036

Current CPI (Mar. 2024) = 131.7762.

Veru Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 0.008 100.560 0.010
201409 0.058 100.428 0.076
201412 -0.034 99.070 -0.045
201503 -0.052 99.621 -0.069
201506 -0.010 100.684 -0.013
201509 0.045 100.392 0.059
201512 -0.014 99.792 -0.018
201603 -0.027 100.470 -0.035
201606 0.013 101.688 0.017
201609 -0.026 101.861 -0.034
201612 0.034 101.863 0.044
201703 -0.068 102.862 -0.087
201706 0.041 103.349 0.052
201709 0.010 104.136 0.013
201712 0.005 104.011 0.006
201803 -0.068 105.290 -0.085
201806 -0.073 106.317 -0.090
201809 -0.044 106.507 -0.054
201812 -0.021 105.998 -0.026
201903 -0.035 107.251 -0.043
201906 -0.007 108.070 -0.009
201909 -0.013 108.329 -0.016
201912 -0.035 108.420 -0.043
202003 -0.034 108.902 -0.041
202006 0.044 108.767 0.053
202009 -0.005 109.815 -0.006
202012 0.007 109.897 0.008
202103 -0.029 111.754 -0.034
202106 -0.135 114.631 -0.155
202109 -0.010 115.734 -0.011
202112 -0.099 117.630 -0.111
202203 -0.047 121.301 -0.051
202206 -0.167 125.017 -0.176
202209 -0.264 125.227 -0.278
202212 -0.408 125.222 -0.429
202303 -0.297 127.348 -0.307
202306 -0.193 128.729 -0.198
202309 -0.101 129.860 -0.102
202312 -0.055 129.419 -0.056
202403 -0.036 131.776 -0.036

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Veru  (STU:FMW) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Veru Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Veru's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Veru (STU:FMW) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Veru Inc (STU:FMW) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
2916 North Miami Avenue, Suite 1000, Miami, FL, USA, 33127
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology and acute respiratory distress syndrome (ARDS). The company is also in the late stage development of certain drugs for management of breast and prostate cancers. It also has a sexual health program which includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in single segment and generates revenue from USA which is the key revenue generating market, South Africa and other regions.

Veru (STU:FMW) Headlines

No Headlines